“LEQEMBI Intravenous Infusion” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
TOKYO and CAMBRIDGE, Mass., Sep 25, 2023 – (JCN Newswire) – TOKYO and CAMBRIDGE, Mass., Sept 25, 2023 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI® Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD…
Read More
0
